ClinicalTrials.gg
CompletedNCT01866007Updated Jan 27, 2020

A Study to Assess the Pharmacokinetic Comparability of Guselkumab (CNTO1959) When Delivered by 2 Different Devices and as 2 Formulations in Healthy Participants

A Phase 1 interventional study of Guselkumab (lyophilized formulation) and Guselkumab (liquid formulation with PFS-U) in Healthy, sponsored by Janssen Research & Development, LLC. Completed at 3 sites in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-01-27.

Sponsored by Janssen Research & Development, LLC (part of Johnson & Johnson) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Sep 2013, 13 years 1 month ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
141
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

The purpose of this study is to evaluate the pharmacokinetic (what the body does to the medication) comparability of guselkumab in lyophilized and liquid formulations. Also to evaluate pharmacokinetic comparability of liquid formulation of guselkumab when delivered as prefilled syringe with UltraSafe Passive Delivery System [PFS-U] or with a prefilled syringe facilitated injection device [PFS FID]) following a single subcutaneous (SC) administration of 100 mg guselkumab in healthy participants.

Read the detailed description

This is an open-label (all people know the identity of the intervention), randomized (the study medication is assigned by chance), parallel study (each group of participants will be treated at the same time) of guselkumab in healthy participants. Approximately 140 participants will be randomly assigned in the ratio 2:2:2:1 in to 4 treatment groups: Group 1 (SC injection of lyophilized formulation), Group 2 (subcutaneous [SC] injection of liquid formulation with PFS-U), Group 3 (SC injection of liquid formulation with PFS-FID), and Group 4 (IV infusion of liquid formulation). The study consists of 3 phases: screening (up to 4 weeks), open-label treatment and inpatient follow up (1 week) and outpatient follow up (11 weeks). Safety evaluations will include assessment of adverse events, vital signs, physical examination, electrocardiograms, injection-site reactions, and clinical laboratory tests. The total duration of the study for each participant will be approximately 16 weeks.

02

Conditions studied

  • Healthy

Keywords

  • Healthy
  • Guselkumab
  • CNTO1959
  • Pharmacokinetics
  • UltraSafe Passive Delivery System (PFS-U)
  • Prefilled syringe facilitated injection device (PFS FID)
03

In context

Lead sponsor

Janssen Research & Development, LLC is the lead sponsor of 932 studies on the registry; 76 are open to participants now.

Of its 285 completed or terminated interventional studies of FDA-regulated products, 137 (48%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy participant with no abnormalities
  • Have a weight in the range of 60 kg to 90 kg for male participants; have a weight in the range of 50 kg to 80 kg for female participants
  • Have a (BMI) of 18.5 kg/m2 to 29.0 kg/m2
  • Agrees to protocol-defined use of effective

Exclusion criteria

Exclusion Criteria:

  • Participant has a history of any medical illness including liver or renal insufficiency; significant cardiac, vascular, pulmonary, gastrointestinal, endocrine, neurologic, hematologic, rheumatologic, psychiatric, or metabolic disturbances, ophthalmological disorders, neoplastic disease, urinary tract diseases, or dermatological disease
  • Currently have any known or have a history of malignancy
  • Participant has a known or suspected intolerance or to any biologic medication or known allergies or clinically significant reactions to murine, chimeric, or human proteins to monoclonal antibodies or antibody fragments
  • Have had a Bacillus Calmette-Guérin (BCG) vaccination within 12 months of screening
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
141 participants (actual)

Study arms

  • Experimental
    Group 1

    40 participants will receive a single subcutaneous (SC) injection of 100 mg guselkumab prepared from lyophilized formulation.

    Drug: Guselkumab (lyophilized formulation)

  • Experimental
    Group 2

    40 participants will receive a single SC injection of 100 mg guselkumab, liquid formulation with UltraSafe Passive Delivery System (PFS-U).

    Drug: Guselkumab (liquid formulation with PFS-U)

  • Experimental
    Group 3

    40 participants will receive a single SC injection of 100 mg guselkumab, liquid formulation with a prefilled syringe facilitated injection device (PFS FID).

    Drug: Guselkumab (liquid formulation with PFS FID)

  • Experimental
    Group 4

    20 participants will receive a single intravenous (IV) infusion of 100 mg guselkumab prepared from liquid formulation.

    Drug: Guselkumab (liquid formulation)

Interventions

  • Participants will receive a single SC injection of 100 mg guselkumab prepared from lyophilized formulation.

    Also known as: CNTO1959

  • DrugGuselkumab (liquid formulation with PFS-U)

    Drug page: Guselkumab

    Participants will receive a single SC injection of 100 mg guselkumab, liquid formulation with PFS-U.

    Also known as: CNTO1959

  • DrugGuselkumab (liquid formulation with PFS FID)

    Drug page: Guselkumab

    Participants will receive a single SC injection of 100 mg guselkumab, liquid formulation with PFS FID.

    Also known as: CNTO1959

  • Participants will receive a single IV infusion of 100 mg guselkumab prepared from liquid formulation.

    Also known as: CNTO1959

06

What researchers measure

Primary outcomes

  1. Maximum observed serum concentration (Cmax) of guselkumab

    Time frame: Day 1 through Week 12

  2. Area under the curve (AUC) from time 0 to 70 days of guselkumab

    Time frame: Day 1 through Week 12

Secondary outcomes

  1. Absolute bioavailability of guselkumab

    Bioavailability will be evaluated by using formula: AUC from time zero to infinity with extrapolation of the terminal phase of SC injection divided by AUC from time zero to infinity with extrapolation of the terminal phase of IV infusion of guselkumab and multiplied by 100.

    Time frame: Day 1 through Week 12

  2. Immunogenicity of guselkumab

    Plasma levels of antibodies to guselkumab for evaluation of potential immunogenicity.

    Time frame: Day 1 through Week 12

  3. Number of participants with adverse events as a measure of safety and tolerability

    Time frame: Up to 12 weeks

07

Study locations

3 sites
  • Tempe, Arizona, United States
  • Lincoln, Nebraska, United States
  • Neptune, New Jersey, United States
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2013 to primary completion in Sep 2013, 4 months.

How these figures are worked out, and which studies are left out of them.

Registered
May 28, 2013
First posted
May 31, 2013
StartActual
May 9, 2013
Primary completionActual
Sep 20, 2013
CompletionActual
Oct 9, 2013
Last update
Jan 27, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 27, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01866007
Responsible party
Sponsor
First posted
May 31, 2013
Start date
May 9, 2013
Primary completion
Sep 20, 2013
Completion
Oct 9, 2013
Last update
Jan 27, 2020

Study contacts

Janssen Research & Development, LLC Clinical Trial
study director · Janssen Research & Development, LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Guselkumab

Start the discussion